A Study of Lebrikizumab in Patients with Persistent Moderate to Severe Atopic Dermatitis

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-000049-56

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of this study is to evaluate the efficacy and safety of lebrikizumab used as adjunctive therapy with topical corticosteroid (TCS) compared with TCS alone in patients with persistent moderate to severe atopic dermatitis.


Critère d'inclusion

  • Atopic dermatitis